Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 716 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07201025Recruiting
MRI study of kidney disease in ARPKD
This study uses MRI scans to track kidney disease progression in children and adults with ARPKD. It aims to better understand how the disease changes over time, which could help improve future care.
Cleveland, OhioAges 6 years+ - NCT04875611RecruitingPhase 2
Nivolumab for nasopharyngeal cancer after platinum chemotherapy
This trial studies nivolumab (an immune therapy) for nasopharyngeal cancer that grew or returned after platinum chemotherapy. It aims to shrink tumors or slow cancer growth after standard treatment hasn’t worked.
BialystokAges 18 years+ - NCT06943326Recruiting
How food given through a tube affects recovery in sepsis patients
This trial tests if the type of tube feeding given to sepsis patients in the ICU can affect their recovery. It aims to find the best diet to help fight the infection and prevent complications.
SanliurfaAges 18 years+ - NCT07187531RecruitingPhase 2
Testing a new drug to preserve insulin production in type 1 diabetes
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
San Francisco, CaliforniaAges 5–40 - NCT07180797Enrolling by invitation
Training urologists on a new robot for prostate surgery
This study tests a training program for urologists and urology residents to learn how to use a new Hugo RAS robot for nerve-sparing prostate removal. It aims to see if the program helps them gain the skills they need.
MelleAges 18 years+ - NCT07182721RecruitingPhase 2
Study of SKB264 plus Inetetamab for advanced HER2+ breast cancer after T-DXd
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT06949865Recruiting
AI-enhanced levodopa challenge test for parkinsonism
This study uses artificial intelligence (AI) to improve a standard test for parkinsonism called the levodopa challenge test. It may help doctors better understand how your movement symptoms respond to levodopa, a common Parkinson's medication.
BeijingAges 50–75 - NCT06922526Recruiting
Pacemaker and tricuspid valve health: long-term outcomes
This study looks at how pacemakers and similar heart devices affect the tricuspid valve over time and whether that leads to worse health outcomes. It may help you understand if your device is causing long-term changes.
JinanAges 18 years+ - NCT07166094RecruitingPhase 3
Rina-S vs standard therapy for advanced endometrial cancer
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
Mobile, AlabamaAges 18 years+ - NCT07173829Recruiting
Study of why glioblastoma comes back
This trial collects tumor samples to study what causes glioblastoma to return. It may help scientists find better treatments.
BordeauxAges 18 years+ - NCT05778617RecruitingPhase 3
Ambroxol to Slow Parkinson’s Disease Progression
This trial studies whether ambroxol (or a placebo) can slow the progression of Parkinson’s disease. It may help by aiming to change how the disease develops over time.
BirminghamAges 35–75 - NCT07158216Recruiting
Long-term effects of brain stimulation in primary progressive aphasia
This study tests whether brain stimulation can help people with primary progressive aphasia (a type of dementia that mainly affects language) maintain or improve their communication skills over time. It looks at two types of stimulation: transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS).
MadridAges 18 years+ - NCT07150806RecruitingPhase 1/Phase 2
RYZ101 for progressive or recurrent meningioma
This trial is testing an investigational drug, RYZ101, for people with a type of brain tumor called meningioma that has grown back or not responded to other treatments. The goal is to see if RYZ101 can help stop the tumor from growing, and to check its safety. It might be an option if you have already had surgery or radiation.
Columbus, OhioAges 18 years+ - NCT07152197Recruiting
Resistance Exercise for Charcot-Marie-Tooth Disease
This trial tests whether resistance exercises (like lifting weights with your legs) can help people with Charcot-Marie-Tooth disease. It is for young adults aged 15 to 29 who can move their ankle enough to do strength training.
Temuco, La AraucaníaAges 15–29 - NCT07137871RecruitingPhase 1
Avasopasem for advanced HR+ breast cancer after CDK 4/6 inhibitor
This trial tests a drug called avasopasem for people with hormone receptor-positive, HER2-negative breast cancer that has spread and gotten worse despite treatment with a CDK 4/6 inhibitor (ribociclib or abemaciclib) and hormonal therapy. It aims to see if adding avasopasem can help control the cancer.
San Antonio, TexasAges 18 years+ - NCT07117630RecruitingPhase 2
A new drug combo for advanced breast cancer after standard treatment
This trial tests a new drug combination for women with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after standard treatments like CDK4/6 inhibitors and hormone therapy. It aims to see if the combination can help when other options have stopped working.
ShanghaiAges 18 years+ - NCT07120529Recruiting
Comparing two types of hysterectomy for early cervical cancer
This study looks at two ways to remove the uterus and cervix for early-stage cervical cancer: minimally invasive surgery (like laparoscopic or robotic) versus open surgery (traditional large incision). It checks whether the less invasive approach works just as well in terms of survival and keeping the cancer from coming back.
BialystokAges 18–85 - NCT07121842Recruiting
New MRI scan to track glioblastoma growth during treatment
This study is testing a new type of MRI called APTw-CEST to see if it can better detect tumor progression in people with glioblastoma. It may help doctors monitor your tumor more accurately during radiation or chemoradiation therapy.
AmsterdamAges 18 years+ - NCT07106762RecruitingPhase 2/Phase 3
Study of new targeted drug vs chemo for bladder cancer
This trial tests a new drug called Izalontamab Brengitecan (a targeted therapy that delivers chemo straight to cancer cells) against standard platinum chemotherapy for people whose bladder cancer worsened after immunotherapy. It may be an option if you are fit for chemo but haven't had platinum chemo recently.
Gilbert, ArizonaAges 18 years+ - NCT07112066Recruiting
Heart imaging study for ATTR amyloidosis patients
This study uses heart imaging to track disease progression in people with ATTR cardiac amyloidosis who are about to start tafamidis treatment. It aims to understand how the disease changes over time.
Zurich, Canton of ZurichAges Any age - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07104331RecruitingPhase 2
Testing nab-sirolimus for epithelioid hemangioendothelioma
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
Stanford, CaliforniaAges 18 years+ - NCT07096609RecruitingPhase 1/Phase 2
Lenvatinib for GIST after imatinib, sunitinib, and regorafenib
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
SeoulAges 20 years+ - NCT06351670Recruiting
Monitoring early to moderate age-related macular degeneration with AI
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
ViennaAges 55–99
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 716 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.